Cyclo Therapeutics, Inc.
CYTH
$0.7206
$0.00991.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -8.51% | 24.66% | -15.51% | -21.76% | -46.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.51% | 24.66% | -15.51% | -21.76% | -46.35% |
| Cost of Revenue | -19.45% | 5.88% | -27.97% | -34.36% | -54.28% |
| Gross Profit | -7.30% | 26.73% | -14.04% | -20.22% | -45.30% |
| SG&A Expenses | 35.39% | 16.52% | -0.30% | -12.80% | -9.62% |
| Depreciation & Amortization | -40.93% | -28.57% | -14.87% | -1.03% | 3.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.59% | 12.68% | 11.83% | 24.29% | 33.77% |
| Operating Income | -27.26% | -12.10% | -13.89% | -28.35% | -44.36% |
| Income Before Tax | -27.86% | -9.90% | -9.65% | -29.81% | -46.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.86% | -9.90% | -9.65% | -29.81% | -46.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.86% | -9.90% | -9.65% | -29.81% | -46.24% |
| EBIT | -27.26% | -12.10% | -13.89% | -28.35% | -44.36% |
| EBITDA | -27.33% | -12.14% | -13.92% | -28.38% | -44.41% |
| EPS Basic | 44.64% | 51.46% | 47.24% | 27.05% | -2.85% |
| Normalized Basic EPS | 49.63% | 53.19% | 47.29% | 27.83% | -1.64% |
| EPS Diluted | 44.58% | 51.40% | 47.24% | 27.05% | -2.85% |
| Normalized Diluted EPS | 49.63% | 53.19% | 47.29% | 27.83% | -1.64% |
| Average Basic Shares Outstanding | 117.44% | 127.68% | 122.72% | 87.73% | 52.29% |
| Average Diluted Shares Outstanding | 117.44% | 127.68% | 122.72% | 87.73% | 52.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
